导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -8.28% | 3645/4773 |
| 近一周 | -3.31% | 4034/5462 |
| 近一月 | -3.09% | 1553/5421 |
| 近一季 | -6.19% | 2013/5209 |
| 近半年 | -18.15% | 4244/4920 |
| 近一年 | -7.67% | 3230/4366 |
| 近两年 | 22.48% | 2593/2954 |
| 近三年 | -4.60% | 1984/2253 |
| 成立以来 | -3.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.15% 1040/4961 |
-6.22% 3674/5312 |
- - |
- - |
| 2025 | 4.82% 3029/4813 |
-6.25% 3345/3635 |
2.01% 1946/4076 |
9.41% 3358/4524 |
0.17% 2159/4813 |
| 2024 | 12.77% 1214/3463 |
4.04% 486/2808 |
- 664/3014 |
8.32% 2755/3129 |
0.07% 1274/3463 |
| 2023 | -7.19% 897/2656 |
12.49% 290/2280 |
0.48% 319/2385 |
-6.34% 1469/2515 |
-12.33% 2456/2655 |
| 2022 | -11.51% 245/2207 |
-3.99% 161/1919 |
1.55% 1457/2016 |
-11.95% 615/2113 |
3.09% 772/2208 |
| 2021 | 23.55% 128/1822 |
7.14% 81/1255 |
-3.16% 1238/1330 |
18.77% 58/1466 |
0.27% 1148/1822 |
| 2020 | -6.07% 970/1250 |
-5.46% 420/1028 |
-4.82% 1044/1067 |
7.59% 771/1164 |
-2.99% 1125/1184 |
| 2019 | 2.11% 809/1092 |
16.96% 664/739 |
-10.47% 739/788 |
-4.08% 758/850 |
1.66% 873/918 |
| 2018 | - - |
- - |
-18.07% 596/631 |
3.05% 89/660 |
-8.40% 91/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 广发中证基建工程ETF联接A VS. 长安沪深300非周期A(740101) |